Solara Active Pharma Sciences Ltd (SOLARA) is currently trading at 629.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Solara Active Pharma Sciences Limited manufactures active pharmaceutical ingredients (APIs) across six Indian manufacturing plants, supplies regulated markets, operates two R&D centres, and has developed 80+ commercial APIs focused on complex chemistries and regulated approvals. Q2 FY27 was the company’s best quarter in about five years: consolidated revenue rose 33% year‑on‑year to INR 418 crore, EBITDA more than doubled to INR 77 crore and PAT swung to INR 28.5 crore from a loss a year ago, despite supply disruptions and pricing pressures. The base business is the primary growth engine, contributing roughly INR 327 crore this quarter with regulated markets accounting for about 78% of revenues; management reports sustained gross margins of 50%+ for base products, underpinning healthier mix and margin expansion potential. Ibuprofen, previously loss‑making, moved close to breakeven this quarter due to temporary market dynamics, higher realizations and volume; however, management has initiated a formal 12‑week strategic review to decide on repurposing, sale or other options for the ibuprofen asset. Balance sheet actions strengthened liquidity and leverage: net debt fell from ~INR 614 crore to ~INR 500 crore in H1 FY27 improving net debt/EBITDA to roughly 1.8x, aided by rights issue proceeds, working capital discipline and monetisation of idle assets.

Over the past 52 weeks, Solara Active Pharma Sciences Ltd has traded between a low of ₹422.85 and a high of ₹774.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Solara Active Pharma Sciences Ltd has a market capitalization of approximately 3,090.05. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Solara Active Pharma Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 83.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 3,090.05 Cr, Solara Active Pharma Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Solara Active Pharma Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Solara Active Pharma Sciences Ltd is 83.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company disclosed that it uploaded the audio recording of its Q2 FY27 earnings call, held on October 16, 2026, covering unaudited results for the quarter ended September 30, 2026.

Solara reported revenue of ₹384.3 crore, EBITDA of ₹63.5 crore, and PAT of ₹16.3 crore for Q1 FY27.

Solara reported Q1 FY27 profit after tax (PAT) of ₹16.3 crore in its Q1’27 earnings update dated July 23, 2026.

The company has scheduled the conference call for July 23, 2026 at 4:00 PM IST to discuss unaudited results for the quarter ended June 30, 2026.